[{"data":1,"prerenderedAt":181},["ShallowReactive",2],{"drug-cinacalcet":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":51,"contraindications":80,"warnings":90,"renal":91,"monitoring":92,"interactions":93,"review":94,"examples":97,"atc":103,"iran":105,"links":125,"populations":142,"usApproval":176},"cinacalcet",1,{"fa":7,"en":8},"سیناکلست","Cinacalcet","systemic-hormones",{"fa":11,"en":12},"کلسیمیمتیک","Calcimimetic",[14],{"name":15,"market":16},"Sensipar","US",[18,19,7],"sensipar","mimpara",[21,35,43],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":30,"refs":31},"tab-30","tablet","oral","30 mg tablet",{"amount":27,"unit":28,"perUnit":23,"scored":29},30,"mg",false,[16],[32],{"source":33,"section":34},"fda-sensipar","3",{"id":36,"form":23,"route":24,"label":37,"concentration":38,"markets":40,"refs":41},"tab-60","60 mg tablet",{"amount":39,"unit":28,"perUnit":23,"scored":29},60,[16],[42],{"source":33,"section":34},{"id":44,"form":23,"route":24,"label":45,"concentration":46,"markets":48,"refs":49},"tab-90","90 mg tablet",{"amount":47,"unit":28,"perUnit":23,"scored":29},90,[16],[50],{"source":33,"section":34},[52],{"id":53,"disease":54,"label":55,"population":58,"type":62,"unit":28,"dose":63,"refs":64,"limits":67,"notes":71},"shpt","secondary-hyperparathyroidism-ckd",{"fa":56,"en":57},"هیپرپاراتیروئیدی ثانویه در دیالیز — شروع ۳۰ mg یک بار در روز","Secondary hyperparathyroidism on dialysis — start 30 mg once daily",{"minAge":59},{"value":60,"unit":61},18,"year","fixed",{"perDose":27,"dosesPerDay":5},[65],{"source":33,"section":66},"2.2",{"maxPerDay":68,"refs":69},180,[70],{"source":33,"section":66},[72],{"text":73,"refs":76},{"fa":74,"en":75},"هر ۲ تا ۴ هفته: ۳۰ → ۶۰ → ۹۰ → ۱۲۰ → ۱۸۰ mg تا iPTH ۱۵۰ تا ۳۰۰. کلسیم و فسفر ظرف ۱ هفته، iPTH ۱ تا ۴ هفته پس از هر تغییر. با غذا؛ قرص کامل.","Every 2–4 weeks: 30 → 60 → 90 → 120 → 180 mg to iPTH 150–300. Calcium and phosphorus within 1 week, iPTH 1–4 weeks after each change. With food; swallow whole.",[77,78],{"source":33,"section":66},{"source":33,"section":79},"2.1",[81],{"id":82,"severity":83,"text":84,"refs":87},"ca","block",{"fa":85,"en":86},"شروع درمان در کلسیم کمتر از حد طبیعی.","Starting treatment when serum calcium is below normal.",[88],{"source":33,"section":89},"4",[],[],[],[],{"status":95,"reviewer":96,"date":96},"unverified",null,[98],{"regimen":53,"formulation":22,"input":99,"expect":102},{"ageYears":100,"weightKg":101},55,70,{"perDose":27,"tabletsPerDoseRounded":5},[104],"H05BX01",{"status":106,"forms":107,"refs":120},"registered",[108,112,116],{"code":109,"en":110,"fa":111},"08066","CINACALCET 30MG TAB","قرص سیناکالست ۳۰ میلی‌گرم",{"code":113,"en":114,"fa":115},"13571","CINACALCET 60MG TAB","قرص سیناکالست ۶۰ میلی‌گرم",{"code":117,"en":118,"fa":119},"13610","CINACALCET 90MG TAB","قرص سیناکالست ۹۰ میلی‌گرم",[121],{"source":122,"section":123,"url":124},"darooyab-generic","G-1431\u002FCinacalcet","https:\u002F\u002Fwww.darooyab.ir\u002FG-1431\u002FCinacalcet",[126,130,134,137,140],{"kind":127,"url":128,"label":129},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=021688","NDA021688",{"kind":131,"url":132,"label":133},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=45028573-13c4-4c8b-ae62-6c75bba97c81","FDA Sensipar",{"kind":135,"url":136,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa605004.html",{"kind":138,"url":139,"label":104},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=H05BX01",{"kind":141,"url":124,"label":8},"darooyab",{"pregnancy":143,"lactation":152,"pediatric":160,"geriatric":168},{"level":144,"text":145,"quote":148,"refs":149},"caution",{"fa":146,"en":147},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary Limited case reports of Sensipar use in pregnant women are insufficient to inform a drug associated risk of adverse developmental outcomes.",[150],{"source":33,"section":151},"8.1",{"level":144,"text":153,"quote":156,"refs":157},{"fa":154,"en":155},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary There are no data regarding the presence of Sensipar in human milk or effects on the breastfed infant or on milk production.",[158],{"source":33,"section":159},"8.2",{"level":144,"text":161,"quote":164,"refs":165},{"fa":162,"en":163},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","The safety and efficacy of Sensipar have not been established in pediatric patients.",[166],{"source":33,"section":167},"8.4",{"level":144,"text":169,"quote":172,"refs":173},{"fa":170,"en":171},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","Of the total number of subjects (n = 1136) in clinical studies of Sensipar, 26 percent were 65 and over, and 9 percent were 75 and over.",[174],{"source":33,"section":175},"8.5",{"kind":177,"refs":178,"id":129},"NDA",[179],{"source":33,"section":180},"SPL approval \u002F marketing category",1792111448713]